A landmark investigation reveals Oregon’s licensed psilocybin service centers are exceeding safety and compliance standards, but economic barriers limit broader access.

Maine warns medical cannabis patients after discovering high levels of microbial contamination in flower and pre-rolls. Understand the science, regulations, and implications for DMV patients.

An in-depth look at Ascend Cannabis in downtown Cincinnati, product delivery methods, scientific pharmacokinetics, and lessons for DMV consumers.

An in-depth look at Midtown Phoenix's Story Cannabis, exploring retail formats, cannabinoid science, safety, and takeaways for DMV consumers.

The end of a Dutch health ministry supply contract forces the legacy medical cannabis pioneer into bankruptcy, shifting global market dynamics.

A major study finds marijuana use rivals prescription meds for those attempting to quit smoking cigarettes, raising new questions for Virginia, DC, and Maryland residents.

A new study shows cannabis is the leading substance used among U.S. hikers—surpassing alcohol and psychedelics. Scientific context, safety, and DMV region implications explored.

New policy research reveals that interactive regulatory QR codes significantly boost consumer trust, safety awareness, and legal market participation.

A large, placebo-controlled study reported meaningful back pain relief and better sleep with a low-dose THC medication—without signs of dependency.

Blackwell Captive teams with Apta Health to add a guided cash‑pay option for employers in its programs, including Humboldt Health, aiming to simplify access and cost control.

High Times reports a small clinical trial of an experimental medication for cannabis withdrawal. Here’s what we know now, how it could work, and what DMV patients should watch.

A practical Black Mamba guide covering its reported genetics, flavor, effects, formats, testing, cultivation, and what DMV cannabis consumers should know.

A Minnesota state analysis of 1,811 autism patients found sustained reductions in moderate-to-severe anxiety and depression after joining the medical cannabis program, with improvements often lasting at least four months.

A University of Michigan–led analysis reported in Annals of Internal Medicine finds a 16% rise since 2020 in U.S. clinicians authorizing medical cannabis, with millions of patients participating.

Oregon pauses a proposed psilocybin fee increase, California earmarks $4.7M for psychedelic research, and the DEA moves to schedule five tryptamines—here’s why it matters.

A massive 2025 YouGov poll shows broad support for medical and adult-use cannabis—and momentum for federal reform that could open banking, research, and interstate trade.

A December 18, 2025 executive order shifts cannabis from Schedule I to Schedule III. Here’s how that could reshape taxes, research, and patient access across the DMV.

A landmark Phase 2 study will test smoked, high-THC flower versus placebo in 320 veteran participants with moderate to severe PTSD. Here’s what’s being studied and why it matters for DMV patients.

How Ken Estes’ legendary cut became a cultural and medical touchstone—and what Granddaddy Purple means for patients and consumers in the DMV today.

State-run research in Minnesota tracked 1,800 autism spectrum disorder patients in its medical program and found sustained reductions in anxiety and depression after starting cannabis.